Clinical Research Directory

PART 1: Inclusion Criteria: 1. Age \> 18 years. 2. Histological or cytological proof of metastatic solid tumors. 3. Currently receiving immune checkpoint inhibitors or other immunologic therapies of interest (to be determined by study principal investigators). 4. Willingness and ability of patient to provide signed voluntary informed consent. Exclusion Criteria: 1. Any condition that could interfere with a patient's ability to provide informed consent such as dementia or severe cognitive impairment. 2. Any contraindication to undergoing a venepuncture. PART 2: Inclusion Criteria: 1. Age \> 18 years. 2. Histological or cytological proof of metastatic solid tumors. 3. At least one biopsiable lesion deemed medically accessible and safe to biopsy. 4. Candidate for one or more phase I or II or III clinical trials with immune checkpoint inhibitors at the time of study enrolment. Patients receiving approved immune checkpoint inhibitors or via special access are also eligible. Patients receiving other immunologic therapies of interest may be allowed (to be determined by study principal investigators). 5. Fulfills local institution's laboratory parameters for tumor biopsy. 6. Willingness and ability of patient to provide signed voluntary informed consent. Exclusion Criteria: 1. Any condition that could interfere with a patient's ability to provide informed consent such as dementia or severe cognitive impairment. 2. Any contraindication to undergoing a biopsy procedure. 3. Any contraindication to undergoing a venepuncture.